64th ASH Annual Meeting and Exposition: 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: New Molecular Tools for Precision Diagnostics in Hematology

Symposia: Emerging Tools, Techniques and Artificial Intelligence in Hematology Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, Acute Myeloid Malignancies, ALL, AML, Fundamental Science, clinical trials, adult, Translational Research, Clinical Practice (Health Services and Quality), Non-Biological therapies, assays, Plasma Cell Disorders, Clinical Research, genomics, Chemotherapy, Combination therapy, hematopoiesis, pediatric, Diseases, Therapies, Lymphoid Malignancies, metabolism, Myeloid Malignancies, emerging technologies, Biological Processes, Pharmacology, Technology and Procedures, molecular biology, Study Population, profiling, Human, Minimal Residual Disease , molecular testing, omics technologies, Pathology

208-210 (Ernest N. Morial Convention Center)

Moderators:

Ilaria Iacobucci, PhD, Department of Pathology, St. Jude Children's Research Hospital and Sangmoo Jeong, PhD, Johns Hopkins University

Disclosures:

Iacobucci: Mission Bio: Honoraria.

9:30 AM

493

Genotyping of Multiple Genomic Loci with Chromatin Accessibility Profiling in Single Cells Links Clonal Hierarchy with Epigenetic Variation in Acute Myeloid Leukemia

Sven Turkalj^1,2^*, Niels Asger Jakobsen, BM BCh MRCP^1,2,3^*, Angus Groom, MSc^1,2^*, Marlen Metzner, MSc^1,2^*, Batchimeg Usukhbayar, PhD^1,2^*, Mirian Angulo Salazar, MSc^1,2^*, Kevin Clark, BSc⁴^*, E. Ravza Gür, MSc^1,5^*, Lance D. Hentges, PhD^1,5^*, Paul Sopp⁴^*, James O.J. Davies, MRCP PhD^1,2,3^*, Jim R. Hughes, PhD^1,5^* and Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath^1,2,3

¹MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
²Oxford Centre for Haematology, NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom
³Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
⁴Flow Cytometry Facility, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom
⁵MRC WIMM Centre for Computational Biology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom

9:45 AM

494

Germline SAMD9/9L MDS Predisposition Syndromes Are Characterized By Complex Clonal Architecture and Lineage-Specific Escape Mechanisms Including Somatic Genetic Rescue in T and B Lymphocytes

Charnise Goodings-Harris, PhD¹, Sushree Sangita Sahoo, PhD²^*, Sara Lewis, MS, CGC³^*, Emilia J. Kozyra, MSc⁴^*, Marc Arribas-Layton, PhD⁵^*, Senthilkumar Ramamoorthy, PhD^6,7^*, Rohith Jesudas, MBBS⁸, Nathan Gray, MD⁹^*, Miriam Erlacher, MD, PhD^10,11^*, Charlotte M. Niemeyer^11,12 and Marcin W. Wlodarski, MD, PhD¹³

¹St Jude Children's Research Hospital, Memphis, TN
²Hematology, St. Jude Children's Research Hospital, Memphis, TN
³Department of Hematology, St Jude Children's Research Hospital, Lakeland, TN
⁴University Childrens Hospital Freiburg, Freiburg, Germany
⁵Mission Bio, San Francisco
⁶Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany
⁷Institute of Medical Bioinformatics and Systems Medicine, University of Freiburg, Freiburg, Germany
⁸St Judes Children's Research Hospital, Memphis, TN
⁹Center for Advanced Practice, St. Jude Children's Research Hospital, Memphis
¹⁰Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany
¹¹German Cancer Consortium (DKTK), Heidelberg, Germany
¹²Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
¹³Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN

10:00 AM

495

Unmatched Whole-Genome Sequencing As a Clinical Tool for Hematological Neoplasms with Significant Utility in Cases with Tumor-in-Normal Contamination

Jesús Gutiérrez-Abril, PhD¹^*, Daniel Leongamornlert, PhD²^*, Neerav N Shukla, MD¹^*, Maria Luisa Sulis, MD¹, Yangyu Zhou, BS³^*, Max F. Levine, MS¹^*, Emilio Barretta⁴^*, SooWah Lee, MSc⁵^*, Juan E. Arango-Ossa³^*, Gunes Gundem, PhD¹^*, Juan S. Medina-Martínez³^*, Bela Patel Wrench, MD⁶^*, Anthony V. Moorman⁷, Adele K. Fielding, MBBS, PhD⁸, Andrew L. Kung, MD, PhD¹ and Elli Papaemmanuil, PhD³

¹Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY
²Cancer, Ageing and Somatic Mutation (CASM), Wellcome Sanger Institute, Cambridge, ENG, United Kingdom
³Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
⁴Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
⁵UCL Cancer Institute, London, United Kingdom
⁶Centre for Haemato-Oncology, University College London, London, United Kingdom
⁷Wolfson Childhood Cancer Research Centre, Newcastle University, Newcastle, United Kingdom
⁸Cancer Institute, University College London, London, United Kingdom

10:15 AM

496

Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)

Piyanuch Kongtim, MD¹, Mary-Elizabeth M. Percival, MD², Timothy J Martins, PhD³^*, Guangrong Qin, PhD⁴^*, Niall Curley²^*, Kelda M. Gardner, PA-C⁵^*, Sylvia Chien, MS²^*, Jin Dai, PhD²^*, Vivian G. Oehler, MD⁶^*, C. Anthony Blau, MD⁷^*, Paul C. Hendrie, MD, PhD², Ryan D. Cassaday, MD², Anna B. Halpern, MD², Bart L. Scott, MD^8,9, Roland B. Walter, MD, PhD, MS^2,10, Heather Smith, PA-C¹¹^*, Guido Marcucci, MD¹² and Pamela S. Becker, MD, PhD^13,14

¹Division of Hematology-Oncology, Department of Medicine, University of California Irvine, Orange, CA
²Department of Medicine, University of Washington, Seattle, WA
³Institute for Stem Cell and Regenerative Medicine/Department of Medicine, University of Washington, Seattle, WA
⁴Institute for Systems Biology, Seattle, WA
⁵Division of Hematology, Department of Medicine, University of Washington, Seattle, WA
⁶Fred Hutchinson Cancer Center, Seattle, WA
⁷All4cure, Seattle, WA
⁸Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, WA
⁹Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
¹⁰Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
¹¹University of Washington (UW), Seattle, WA
¹²Department of Hematologic Malignancies Translational Science, Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, Beckman Research Institute, City of Hope National Medical Center, Duarte, CA
¹³Division of Hematology and Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA
¹⁴Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

10:30 AM

497

A Dynamic Personalized Human 3D Organoid for the Study of the Tumor Microenvironment and Metabolism in Acute Myeloid Leukemia Using Patient-Derived Xenografts

Alejandro De Janon, MSc¹, Madison Stout²^*, Diana Fridlyand, MD², Zhou Fang³^*, Ahmet F. Coskun, PhD³^*, Douglas K Graham, MD, PhD², Athanasios Mantalaris, PhD¹^*, Deborah DeRyckere, BS, PhD⁴ and Nicki Panoskaltsis, MD, PhD^1,5

¹BioMedical Systems Engineering Laboratory, Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA
²Aflac Cancer & Blood Disorders Center, Emory University, Atlanta, GA
³W.H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA
⁴Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
⁵Winship Cancer Institute, Emory University, Atlanta, GA

10:45 AM

498

Liquid Biopsy-Based Next-Generation Sequencing Is an Alternative to Tissue Molecular Profiling of Lymphoid, Plasma-Cell, and Myeloid Neoplasms

Douglas A Mata, MD, MPH¹^*, Jessica K Lee, MS¹^*, Brennan Decker, MD, PhD¹^*, Vignesh Shanmugam, MD^2,3^*, Chelsea B Marcus, MD¹^*, Hanna Tukachinsky, PhD¹^*, Alexa B Schrock, PhD¹^*, Nimesh R Patel, MD¹^*, Jeffrey S Ross, MD¹^*, Geoffrey R Oxnard, MD¹^*, Jo-Anne Vergilio, MD¹^*, Kamran M Mirza, MBBS, PhD⁴, Mina L Xu, MD⁵^* and Jamal K Benhamida, MD⁶^*

¹Foundation Medicine, Cambridge, MA
²Broad Institute of MIT and Harvard, Cancer Program, Cambridge, MA
³Department of Pathology, Brigham and Women's Hospital, Boston, MA
⁴Loyola University Health System, Maywood, IL
⁵Yale University School of Medicine and Yale Cancer Center, New Haven, CT
⁶Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

803.O2.6 803. Emerging Tools, Techniques and Artificial Intelligence in Hematology: New Molecular Tools for Precision Diagnostics in Hematology